SAR445514

P1/2, N=32, Terminated, Sanofi | Trial completion date: Apr 2028 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> May 2025; Early discontinuation based on sponsor decision not driven by any safety concerns.

P1/2, N=32, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=111 --> 32

P1/2, N=111, Recruiting, Sanofi | Trial primary completion date: Apr 2026 --> Mar 2027

P1/2, N=111, Recruiting, Sanofi | Trial completion date: Aug 2027 --> Mar 2028

P1/2, N=101, Recruiting, Sanofi | Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2026

P1/2, N=101, Recruiting, Sanofi | Not yet recruiting --> Recruiting

Importantly, SAR’514 exhibits ex vivo efficacy using bone marrow mononuclear cells (BMMC) from MM patients in an autologous setting showing an active and efficient primary MM cell killing against MM cells from patients that have failed diverse therapies, including standard of care treatments. In summary, these results demonstrate the efficacy of SAR’514 for controlling MM tumors in vivo and ex vivo, and provide consistent support for its clinical development.

As compared to the control group in which only 20% of mice survived with a median survival day of 44.5 days, SAR'514 induced a significant mouse survival from 0.5 mg/kg to 5 mg/kg with an overall survival of 90% and a median survival day over 90 days. In summary, these results demonstrate the efficacy of SAR'514 for controlling MM tumors in vivo and provide consistent support for its clinical development.